239 related articles for article (PubMed ID: 30657911)
21. Clinical characteristics in two patients with partial lipodystrophy and Type A insulin resistance syndrome due to a novel heterozygous missense mutation in the insulin receptor gene.
Iwanishi M; Kusakabe T; Azuma C; Tezuka Y; Yamamoto Y; Ito-Kobayashi J; Washiyama M; Morimoto M; Ebihara K
Diabetes Res Clin Pract; 2019 Jun; 152():79-87. PubMed ID: 31102683
[TBL] [Abstract][Full Text] [Related]
22. Metreleptin for the treatment of progressive encephalopathy with/without lipodystrophy (PELD) in a child with progressive myoclonic epilepsy: a case report.
Pedicelli S; de Palma L; Pelosini C; Cappa M
Ital J Pediatr; 2020 Oct; 46(1):158. PubMed ID: 33099310
[TBL] [Abstract][Full Text] [Related]
23. Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy.
Oral EA; Gorden P; Cochran E; Araújo-Vilar D; Savage DB; Long A; Fine G; Salinardi T; Brown RJ
Endocrine; 2019 Jun; 64(3):500-511. PubMed ID: 30805888
[TBL] [Abstract][Full Text] [Related]
24. Rationale for leptin-replacement therapy for severe lipodystrophy.
Oral EA; Chan JL
Endocr Pract; 2010; 16(2):324-33. PubMed ID: 20061299
[TBL] [Abstract][Full Text] [Related]
25. Metreleptin: first global approval.
Chou K; Perry CM
Drugs; 2013 Jun; 73(9):989-97. PubMed ID: 23740412
[TBL] [Abstract][Full Text] [Related]
26. Facial soft tissue volume decreases during metreleptin treatment in patients with partial and generalized lipodystrophy.
Miehle K; Stumvoll M; Fasshauer M; Hierl T
Endocrine; 2017 Nov; 58(2):262-266. PubMed ID: 28993984
[TBL] [Abstract][Full Text] [Related]
27. A Report of Three Cases With Acquired Generalized Lipodystrophy With Distinct Autoimmune Conditions Treated With Metreleptin.
Lebastchi J; Ajluni N; Neidert A; Oral EA
J Clin Endocrinol Metab; 2015 Nov; 100(11):3967-70. PubMed ID: 26390101
[TBL] [Abstract][Full Text] [Related]
28. Treatment Options for Lipodystrophy in Children.
Mainieri F; Tagi VM; Chiarelli F
Front Endocrinol (Lausanne); 2022; 13():879979. PubMed ID: 35600578
[TBL] [Abstract][Full Text] [Related]
29. Metreleptin improves blood glucose in patients with insulin receptor mutations.
Brown RJ; Cochran E; Gorden P
J Clin Endocrinol Metab; 2013 Nov; 98(11):E1749-56. PubMed ID: 23969187
[TBL] [Abstract][Full Text] [Related]
30. Metreleptin therapy lowers plasma angiopoietin-like protein 3 in patients with generalized lipodystrophy.
Muniyappa R; Abel BS; Asthana A; Walter MF; Cochran EK; Remaley AT; Skarulis MC; Gorden P; Brown RJ
J Clin Lipidol; 2017; 11(2):543-550. PubMed ID: 28502512
[TBL] [Abstract][Full Text] [Related]
31. Characterisation of adiponectin multimers and the IGF axis in humans with a heterozygote mutation in the tyrosine kinase domain of the insulin receptor gene.
Højlund K; Beck-Nielsen H; Flyvbjerg A; Frystyk J
Eur J Endocrinol; 2012 Mar; 166(3):511-9. PubMed ID: 22189999
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of Metreleptin Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants.
Sekizkardes H; Cochran E; Malandrino N; Garg A; Brown RJ
J Clin Endocrinol Metab; 2019 Aug; 104(8):3068-3076. PubMed ID: 31194872
[TBL] [Abstract][Full Text] [Related]
33. Lymphoma in acquired generalized lipodystrophy.
Brown RJ; Chan JL; Jaffe ES; Cochran E; DePaoli AM; Gautier JF; Goujard C; Vigouroux C; Gorden P
Leuk Lymphoma; 2016; 57(1):45-50. PubMed ID: 25864863
[TBL] [Abstract][Full Text] [Related]
34. The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide.
Akinci B; Meral R; Rus D; Hench R; Neidert AH; DiPaola F; Westerhoff M; Taylor SI; Oral EA
Endocrinol Diabetes Metab Case Rep; 2020 Mar; 2020():. PubMed ID: 32213649
[TBL] [Abstract][Full Text] [Related]
35. Molecular characterization of a novel p.R118C mutation in the insulin receptor gene from patients with severe insulin resistance.
Alzahrani AS; Zou M; Baitei EY; Parhar RS; Al-Kahtani N; Raef H; Almahfouz A; Amartey JK; Al-Rijjal R; Hammami R; Meyer BF; Al-Mohanna FA; Shi Y
Clin Endocrinol (Oxf); 2012 Apr; 76(4):540-7. PubMed ID: 22017372
[TBL] [Abstract][Full Text] [Related]
36. Recent advances in understanding lipodystrophy: a focus on lipodystrophy-associated cardiovascular disease and potential effects of leptin therapy on cardiovascular function.
Bruder-Nascimento T; Kress TC; Belin de Chantemele EJ
F1000Res; 2019; 8():. PubMed ID: 31656583
[TBL] [Abstract][Full Text] [Related]
37. Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy.
Akinci G; Akinci B
Recent Pat Endocr Metab Immune Drug Discov; 2015; 9(2):74-8. PubMed ID: 26556498
[TBL] [Abstract][Full Text] [Related]
38. Lipodystrophies in non-insulin-dependent children: Treatment options and results from recombinant human leptin therapy.
Calcaterra V; Magenes VC; Rossi V; Fabiano V; Mameli C; Zuccotti G
Pharmacol Res; 2023 Jan; 187():106629. PubMed ID: 36566927
[TBL] [Abstract][Full Text] [Related]
39. Leptin Substitution in Patients With Lipodystrophy: Neural Correlates for Long-term Success in the Normalization of Eating Behavior.
Schlögl H; Müller K; Horstmann A; Miehle K; Püschel J; Villringer A; Pleger B; Stumvoll M; Fasshauer M
Diabetes; 2016 Aug; 65(8):2179-86. PubMed ID: 27207511
[TBL] [Abstract][Full Text] [Related]
40. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.
Petersen KF; Oral EA; Dufour S; Befroy D; Ariyan C; Yu C; Cline GW; DePaoli AM; Taylor SI; Gorden P; Shulman GI
J Clin Invest; 2002 May; 109(10):1345-50. PubMed ID: 12021250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
